Added to YB: 2019-03-29
Pitch date: 2019-03-29
OMED [bullish]
OncoMed Pharmaceuticals, Inc.
-16.04%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Company Info
OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence, and metastasis.
Market Cap
$34.4M
Pitch Price
$1.06
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
-4.22
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
OncoMed Pharmaceuticals (OMED)
OMED merger with MPH: $40M mkt cap vs $50M stock consideration + CVRs. $57M cash at Q4, significant burn. 3 CVRs: $35M Celgene TIGIT opt-in (unlikely), NAVI partner + royalties (long shot), additional Celgene payments. ~25% upside from arb + ~90% if TIGIT opted. Speculative, size accordingly.
Read full article (3 min)